Anavex Life Sciences
Christopher Missling, PhD, holds a PhD in Metallorganic Chemistry from Ludwig-Maximilians-Universität München and an MBA from Northwestern University - Kellogg School of Management. Christopher currently serves as President & CEO of Anavex Life Sciences. Previous roles include Head of Investment Banking at Brimberg & Co., Chief Financial Officer at Curis, Inc., and Head of Financial Planning at Aventis. Additionally, Christopher has experience as an Analyst in M&A and Investment Banking at Deutsche Bank.
Anavex Life Sciences
Anavex Life Sciences Corp.(www.anavex.com) is a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. Anavex is currently in a Phase 2a trial for Alzhei...